Racial and Ethnic Disparities in Prescribing of GLP-1 Receptor Agonists in the United States: A Retrospective Cohort Analysis

Competing Interest Statement

Outside of the submitted work during the 36 months prior to publication, KK reports honoraria, consulting, sponsored research, writing assistance, licensing, or co-development in the past three years with Hitachi, Pfizer, RTI International, the University of California at San Francisco, Indiana University, the Regenstrief Foundation, the Korean Society of Medical Informatics, the University of Nebraska, NORC at the University of Chicago, the University of Pennsylvania, Yale University, Elsevier, MD Aware, Custom Clinical Decision Support, and the U.S. Office of the National Coordinator for Health IT (via Security Risk Solutions) in the area of health information technology. KK was also an unpaid board member of the non-profit Health Level Seven International health IT standard development organization, he is an unpaid member of the U.S. Health Information Technology Advisory Committee, and he has helped develop a number of health IT tools which may be commercialized to enable wider impact. None of these relationships have direct relevance to the manuscript but are reported in the interest of full disclosure. Outside of the submitted, RH serves on a Data Safety Monitoring Board for Astellas Pharmaceuticals. Other authors have no conflict of interest to report.

Funding Statement

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. JCF and RG were partially funded by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UM1TR004409. MJO was partially funded by the National Institute of Diabetes and Digestive and Kidney Diseases under Award Number P30DK092949

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

University of Utah IRB

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes